Literature DB >> 11461092

The relationship between radiation-induced G(1)arrest and chromosome aberrations in Li-Fraumeni fibroblasts with or without germline TP53 mutations.

J M Boyle1, A Spreadborough, M J Greaves, J M Birch, J M Varley, D Scott.   

Abstract

We previously showed that cultured fibroblasts from patients with the cancer-prone Li-Fraumeni (LF) syndrome, having heterozygous germline TP53 mutations, sustain less ionizing radiation-induced permanent G(1)arrest than normal fibroblasts. In contrast, fibroblast strains from LF patients without TP53 mutations showed normal G(1)arrest. We have now investigated the relationship between the extent of G(1)arrest and the level of structural chromosome damage (mainly dicentrics, rings and acentric fragments) in cells at their first mitosis after G(1)irradiation, in 9 LF strains with TP53 mutations, 6 without TP53 mutations and 7 normal strains. Average levels of damage in the mutant strains were 50% higher than in normals, whereas in non-mutant LF strains they were 100% higher. DNA double strand breaks (dsb) are known to act as a signal for p53-dependent G(1)arrest and to be the lesions from which chromosome aberrations arise. These results suggest that a minimal level of dsb is required before the signal for arrest is activated and that p53-defective cells have a higher signal threshold than p53-proficient cells. Dsb that do not cause G(1)blockage can progress to mitosis and appear as simple deletions or interact to form exchange aberrations. The elevated levels in the non-mutant strains may arise from defects in the extent or accuracy of dsb repair. In LF cells with or without TP53 mutations, the reduced capacity to eliminate or repair chromosomal damage of the type induced by ionising radiation, may contribute to cancer predisposition in this syndrome.

Entities:  

Mesh:

Year:  2001        PMID: 11461092      PMCID: PMC2364041          DOI: 10.1054/bjoc.2001.1896

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  22 in total

1.  Cancer. p53, guardian of the genome.

Authors:  D P Lane
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

2.  Cell cycle arrest defect in Li-Fraumeni Syndrome: a mechanism of cancer predisposition?

Authors:  K J Williams; J M Boyle; J M Birch; J D Norton; D Scott
Journal:  Oncogene       Date:  1997-01-23       Impact factor: 9.867

3.  Susceptibility to radiation-carcinogenesis and accumulation of chromosomal breakage in p53 deficient mice.

Authors:  J M Lee; J L Abrahamson; R Kandel; L A Donehower; A Bernstein
Journal:  Oncogene       Date:  1994-12       Impact factor: 9.867

4.  Different sensitivity to cell killing and chromosome mutation induction by gamma rays in two human lymphoblastoid cell lines derived from a single donor: possible role of apoptosis.

Authors:  J L Schwartz; R Jordan; B A Sedita; M J Swenningson; J P Banáth; P L Olive
Journal:  Mutagenesis       Date:  1995-05       Impact factor: 3.000

5.  Cytogenetic response to G2-phase X irradiation in relation to DNA repair and radiosensitivity in a cancer-prone family with Li-Fraumeni syndrome.

Authors:  R Parshad; F M Price; K F Pirollo; E H Chang; K K Sanford
Journal:  Radiat Res       Date:  1993-11       Impact factor: 2.841

6.  Effect of confluent holding on potentially lethal damage repair, cell cycle progression, and chromosomal aberrations in human normal and ataxia-telangiectasia fibroblasts.

Authors:  J B Little; H Nagasawa
Journal:  Radiat Res       Date:  1985-01       Impact factor: 2.841

7.  Absence of radiation-induced G1 arrest in two closely related human lymphoblast cell lines that differ in p53 status.

Authors:  J B Little; H Nagasawa; P C Keng; Y Yu; C Y Li
Journal:  J Biol Chem       Date:  1995-05-12       Impact factor: 5.157

8.  A possible screening test for inherited p53-related defects based on the apoptotic response of peripheral blood lymphocytes to DNA damage.

Authors:  R S Camplejohn; P Perry; S V Hodgson; G Turner; A Williams; C Upton; C MacGeoch; S Mohammed; D M Barnes
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

9.  Chromosome instability in fibroblasts derived from Li-Fraumeni syndrome families without TP53 mutations.

Authors:  J M Boyle; A Spreadborough; M J Greaves; J M Birch; D Scott
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

10.  No defect in G1/S cell cycle arrest in irradiated Li-Fraumeni lymphoblastoid cell lines.

Authors:  K J Williams; J Heighway; J M Birch; J D Norton; D Scott
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

View more
  5 in total

1.  Lack of toxicity in a patient with germline TP53 mutation treated with radiotherapy.

Authors:  P Wong; K Han
Journal:  Curr Oncol       Date:  2014-04       Impact factor: 3.677

Review 2.  Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53.

Authors:  Ruoji Zhou; An Xu; Julian Gingold; Louise C Strong; Ruiying Zhao; Dung-Fang Lee
Journal:  Trends Pharmacol Sci       Date:  2017-08-14       Impact factor: 14.819

Review 3.  A Unique Case of Bilateral Thalamic High-Grade Glioma in a Pediatric Patient with LI-Fraumeni Syndrome: Case Presentation and Review of the Literature.

Authors:  Raffaella Messina; Gerardo Cazzato; Teresa Perillo; Vita Stagno; Valeria Blè; Mariachiara Resta; Francesco De Leonardis; Nicola Santoro; Francesco Signorelli; Giuseppe Ingravallo
Journal:  Neurol Int       Date:  2021-04-22

Review 4.  Late onset Li-Fraumeni Syndrome with bilateral breast cancer and other malignancies: case report and review of the literature.

Authors:  Karin Kast; Mechthild Krause; Markus Schuler; Katrin Friedrich; Barbara Thamm; Andrea Bier; Wolfgang Distler; Stefan Krüger
Journal:  BMC Cancer       Date:  2012-06-06       Impact factor: 4.430

5.  Breast Cancer after Radiation Therapy in a Patient with Li-Fraumeni Syndrome: A Case Report.

Authors:  In Na Yoon; Eun Suk Cha; Jeoung Hyun Kim; Jee Eun Lee; Jin Chung
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2021-10-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.